Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
02/06/2026 07:58
BRIEF-Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026 June 2 (Reuters) - Santhera Pharmaceuticals Holding AG SANN.S:
SANTHERA ANNOUNCES ORPHAN DRUG AND PRIORITY REVIEW DESIGNATIONS FOR AGAMREE® (VAMOROLONE) IN SOUTH KOREA
SANTHERA PHARMACEUTICALS - GIFT DESIGNATION MAY SHORTEN REVIEW TIMELINE TO 90 WORKING DAYS IN SOUTH KOREA
SANTHERA PHARMACEUTICALS : NXERA PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION IN SOUTH KOREA DURING 2026
Source text: ID:nGNX5NQxk
Further company coverage: SANN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million